Minimal Residual Disease Monitoring in Radically Treated Non-Small Cell Lung Cancer: Challenges and Future Directions

Circulating tumor DNA (ctDNA) analysis can identify patients with residual disease before it is clinically or radiologically evident. Minimal residual disease (MRD) is an advancing area in the management of radically treated solid tumors. Which MRD assay is optimum and when it should be used is stil...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Sullivan, Hazel M, Feber, Andrew, Popat, Sanjay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089274/
https://www.ncbi.nlm.nih.gov/pubmed/37056631
http://dx.doi.org/10.2147/OTT.S322242

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089274/
https://www.ncbi.nlm.nih.gov/pubmed/37056631
http://dx.doi.org/10.2147/OTT.S322242

Ejemplares similares